Table 2 Impact of prophylactic heparin on clinical outcomes in ARDS patients before and after propensity score matching
Outcome | Before PSM | After PSM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|  | All patients (n = 1498) | Non-heparin (n = 502) | Early heparin users (n = 996) | Adjusted HR (95% CI) | P-value | All patients (n = 1004) | Non-heparin (n = 502) | Early heparin users (n = 502) | Adjusted HR (95% CI) | P-value |
Length of ICU stay, mean (SD) | 4.96 [3.13, 9.25] | 4.29 [2.92, 8.24] | 5.13 [3.33, 9.79] |  |  < 0.001 | 4.79 [3.04, 8.93] | 4.29 [2.92, 8.24] | 5.0 [3.29, 9.16] |  | 0.008 |
Length of hospital stay, mean (SD) | 12.0 [7.0, 21.0] | 12.0 [7.0, 20.0] | 13.0 [8.0, 22.0] | Â | 0.022 | 12.0 [7.0, 21.0] | 12.0 [7.0, 20.0] | 13.0 [8.0, 22.0] | Â | 0.015 |
In-hospital mortality, n (%) | 225 (15.02%) | 90 (17.93%) | 135 (13.55%) | 0.71 (0.54–0.93) | 0.012 | 154 (15.34%) | 90 (17.93%) | 64 (12.75%) | 0.65 (0.47–0.90) | 0.01 |
7-day mortality, n (%) | 95 (6.34%) | 41 (8.17%) | 54 (5.42%) | 0.66 (0.44–0.99) | 0.044 | 70 (6.97%) | 41 (8.17%) | 29 (5.78%) | 0.70 (0.43–1.12) | 0.139 |
14-day mortality, n (%) | 170 (11.35%) | 63 (12.55%) | 107 (10.74%) | 0.83 (0.61–1.13) | 0.238 | 119 (11.85%) | 63 (12.55%) | 56 (11.16%) | 0.85 (0.60–1.23) | 0.395 |
28-day mortality, n (%) | 256 (17.09%) | 100 (19.92%) | 156 (15.66%) | 0.74 (0.57–0.95) | 0.019 | 179 (17.83%) | 100 (19.92%) | 79 (15.74%) | 0.73 (0.54–0.98) | 0.037 |
60-day mortality, n (%) | 329 (21.96%) | 129 (25.70%) | 200 (20.08%) | 0.72 (0.58–0.90) | 0.004 | 229 (22.81%) | 129 (25.70%) | 100 (19.92%) | 0.70 (0.54–0.91) | 0.009 |
90-day mortality, n (%) | 370 (24.70%) | 146 (29.08%) | 224 (22.49%) | 0.71 (0.58–0.88) | 0.002 | 256 (25.50%) | 146 (29.08%) | 110 (21.91%) | 0.68 (0.53–0.87) | 0.002 |